Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Research & Development (2018 - 2025)

Serina Therapeutics' Research & Development history spans 8 years, with the latest figure at $3.7 million for Q3 2025.

  • For Q3 2025, Research & Development rose 51.18% year-over-year to $3.7 million; the TTM value through Sep 2025 reached $12.1 million, up 101.25%, while the annual FY2024 figure was $7.5 million, 213.23% up from the prior year.
  • Research & Development for Q3 2025 was $3.7 million at Serina Therapeutics, up from $3.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.7 million in Q3 2025 and bottomed at $162000.0 in Q3 2022.
  • The 5-year median for Research & Development is $481000.0 (2021), against an average of $1.2 million.
  • The largest YoY upside for Research & Development was 582.05% in 2021 against a maximum downside of 73.46% in 2021.
  • A 5-year view of Research & Development shows it stood at $376000.0 in 2021, then plummeted by 44.68% to $208000.0 in 2022, then skyrocketed by 336.06% to $907000.0 in 2023, then soared by 160.75% to $2.4 million in 2024, then skyrocketed by 54.38% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Research & Development are $3.7 million (Q3 2025), $3.2 million (Q2 2025), and $3.0 million (Q1 2025).